3 款创新药在中国获批,来自强生、阿斯利康、李氏大药厂

Insight数据库
31 Jul

强生“兰泽替尼”获批上市7 月 30 日,NMPA 官网显示,强生第三代 EGFR-TKI“兰泽替尼”在国内获批上市。根据公开资料及既往临床研究,推测该适应症为联用埃万妥单抗一线治疗 EGFR 突变局部晚期或转移性 NSCLC(受理号:JXHS2400009)。截图来自:NMPA 官网国外该适应症的获批基于 III 期临床试验 MARIPOSA(NCT04487080)的积极结果,该试验旨在评估...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10